What is Neumora Therapeutics, Inc.'s (NMRA) StockRank?

MoatMap's StockRank for Neumora Therapeutics, Inc. (NMRA) is 10/100, with a Strong Sell signal. This is a composite score combining Quality (23), Value (35), and Momentum (36) factor ranks across MoatMap's 19,000+ stock universe.

Does Neumora Therapeutics, Inc. have an economic moat?

Neumora Therapeutics, Inc. (NMRA) has a Quality factor score of 23/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Neumora Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Neumora Therapeutics, Inc. (NMRA) is Strong Sell, based on a StockRank of 10/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Neumora Therapeutics, Inc. in?

Neumora Therapeutics, Inc. (NMRA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

NMRA

STRONG SELLREMOVE

Neumora Therapeutics, Inc. · Healthcare · United States · $348M · Avg Vol: $2M/d

StockRank

P/E (TTM)

—

ROE

-148.7%

D/E

0.8x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

A clinical-stage neuroscience biotech company with zero revenue and high R&D cash burn, failing our requirement for predictable owner earnings.

COMPANY DESCRIPTION

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing precision medicines for neurodegenerative and neuropsychiatric diseases. The company employs a data-driven, genomics-informed approach to identify disease mechanisms and target specific patient populations, aiming to improve clinical success rates in challenging therapeutic areas. Neumora is advancing a pipeline of novel small molecules addressing significant unmet needs in central nervous system disorders.

FINANCIAL SUMMARY

Year	2021	2022	2023	2024	CAGR
Revenue	0	0	0	0	—
EPS	-1.56	-0.86	-3.63	-1.53	—
Shares	152M	152M	159M	162M	+6.4%
Debt	2M	8M	5M	2M	-3.3%
Equity	-325M	-447M	469M	287M	-38.8%
Op CF	-75M	-115M	-163M	-183M	—
Inv CF	-817,000	-168M	64M	-71M	—
Fin CF	294M	116M	232M	22M	—

PRICE (1M)-27.0%

SMA 50SMA 200

$1.78

RSI (14)

44.1

52W High

$3.65

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

-147.3%3.3

ROE

-148.7%5.1

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-56.7%3.7

Piotroski

—28.8

Int. Cover

-50.0x6.5

D/E Ratio

0.76x20.8

Current Ratio

5.09x71.0

Value

P/E (TTM)

—N/A

EV/EBITDA

-1.1x64.6

P/FCF

—N/A

P/B

3.0x39.5

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

49%22.4

RS 6M

-23%50.8

SMA 50/200

0.90x34.9

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+33%43.8

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$348M

P/E (Forward)

-2.0x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NMRA are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
NMRA	Neumora Therapeutics, Inc.(you)	$348M	10	STRONG SELL
DMAC	DiaMedica Therapeutics Inc.	$332M	10	STRONG SELL
CMPX	Compass Therapeutics, Inc.	$348M	8	STRONG SELL
IVVD	Invivyd, Inc.	$333M	9	STRONG SELL
LYEL	Lyell Immunopharma, Inc.	$393M	8	STRONG SELL
FBRX	Forte Biosciences, Inc.	$425M	10	STRONG SELL
LXEO	Lexeo Therapeutics, Inc.	$399M	7	STRONG SELL
OCGN	Ocugen, Inc.	$477M	9	STRONG SELL
IMRX	Immuneering Corporation	$327M	16	STRONG SELL
FULC	Fulcrum Therapeutics, Inc.	$454M	13	STRONG SELL

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Neumora Therapeutics, Inc. (NMRA) — Stock Score Summary

Neumora Therapeutics, Inc. (NMRA) has a MoatMap StockRank of 10/100 based on Quality (23/100), Value (35/100), and Momentum (36/100) factor scores. The current signal is STRONG SELL. A clinical-stage neuroscience biotech company with zero revenue and high R&D cash burn, failing our requirement for predictable owner earnings.

Key Financial Metrics

Price	$1.78
Market Cap	$348M
P/E (Forward)	-2.00
Price/Book	2.99
Return on Equity	-148.7%
Return on Invested Capital	-147.3%
Debt/Equity	75.51
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-108M

Neumora Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Neumora Therapeutics, Inc.’s (NMRA) StockRank?: MoatMap’s StockRank for Neumora Therapeutics, Inc. (NMRA) is 10/100, with a Strong Sell signal. It is a composite of Quality (23), Value (35), and Momentum (36) factor ranks across MoatMap’s 19,000+ stock universe.
Does Neumora Therapeutics, Inc. have an economic moat?: Neumora Therapeutics, Inc. (NMRA) has a Quality factor score of 23/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Neumora Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Neumora Therapeutics, Inc. (NMRA) is Strong Sell, based on a StockRank of 10/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Neumora Therapeutics, Inc. in?: Neumora Therapeutics, Inc. (NMRA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).